Journal Browser

Go Edit a Special Issue


Special Issue Title:

Diagnosis and treatment of clinically localized prostate cancer: a urological conundrum

Deadline for manuscript submissions: 31 March 2022

Print Special Issue Flyer (5)

Special Issue Editor

  • Guest Editor

    Angelo NaselliE-MailWebsite

    Chief of Urology Department, Ospedale Classificato San Giuseppe, gruppo Multimedica, Milano (MI), Italy; Adjunct professor of Anatomy and Physiology, bachelor’s degree of Nursing and Midwifery course of study, Milan University, Milano (MI), Italy

    Interests: Bladder, prostate, kidney cancer mainly

Special Issue Information

Prostate cancer (PC) is the most common urological malignancy. Estimated new cases and mortality are respectively 13.1% of new cancers and 5.6% of all cancer deaths in 2021 according to the SEER program database The prevalence of incidental PC is high as it is found in about 60% of man aged 80 or more years. Even patients of 60 or more years with a baseline PSA of 4 or less have a 15% risk of being detect with PC by biopsy. Therefore, the chance to be diagnosed with PC is sensibly high at any age after testing for PSA. The benefit of an early diagnosis is not yet fully understood. PLCO and ERSCP trials did not give a final answer to the dilemma. After a diagnosis of clinically localized PC, the main issue is to identify which patients will benefit from treatment and which treatment fits more according to patient and disease characteristics. The SPCG-4, PIVOT and ProtecT trials did not disclose a clear advantage of treatment versus observation and of any treatment versus another. Active surveillance and multiparametric MR of the prostate are relatively new modalities which may help identify patients at risk. Meanwhile, technological improvements of treatments and related costs skyrocketed making PC one of the more controversial disease of the modern history.

The aim of the special issue is to give an insight in the topic. Beside well-known and established studies, reporting the own clinical experience or, alternatively, enlighten with a different interpretation of available data may really help to improve the treatment of our patients.


prostatic neoplasms, early diagnosis, mortality

Manuscript Submission Information

Submissions will be accepted on a rolling basis and reviewed by experts in the field. Rapid peer review and prompt editorial decisions will ensure that quality manuscripts are published on time. The manuscript has not already been published or submitted elsewhere (except conference proceedings papers). If similar work has been published or submitted elsewhere, you must provide a copy of the submitted manuscript. You may not submit your manuscript elsewhere while it is under consideration at the Journal of Men's Health. All manuscripts undergo thorough double-blind peer-review. To check the suitability of the special issue for publishing your manuscript, please read the journal's aims and scope and read or download the guide for authors. You may also send a brief abstract of your work (about 100 words) to the Editorial Office at A guide for authors and other relevant information for manuscript submission is available on the Instructions for Authors page.

Academic Writing and English Language Editing Services

Authors who feel that their manuscript may benefit from additional academic writing or language editing support before submission are strongly encouraged to use academic editing services.

Article Processing Charges (APC)

All manuscripts submitted to the Journal of Men's Health are assessed according to the journal standard editorial criteria. If accepted for publication, an Article Processing Charge of 1250 USD applies.

Type of Articles: Original Research, Review, Mini-Review, Systematic Review, Short Communication, Case Report, Letter to the Editor, Commentary, Rapid Report, Meeting Report, News and Views

Share This Special Issue

Published Papers (0 papers)

Abstracted / indexed in

Science Citation Index Expanded Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Social Sciences Citation Index Social Sciences Citation Index contains over 3,400 journals across 58 social sciences disciplines, as well as selected items from 3,500 of the world’s leading scientific and technical journals. More than 9.37 million records and 122 million cited references date back from 1900 to present.

Current Contents - Social & Behavioral Sciences Current Contents - Social & Behavioral Sciences provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in the social and behavioral sciences.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

SCOPUS Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

DOAJ DOAJ is a community-curated online directory that indexes and provides access to high quality, open access, peer-reviewed journals.

CrossRef Crossref makes research outputs easy to find, cite, link, assess, and reuse. Crossref committed to open scholarly infrastructure and collaboration, this is now announcing a very deliberate path.

Portico Portico is a community-supported preservation archive that safeguards access to e-journals, e-books, and digital collections. Our unique, trusted process ensures that the content we preserve will remain accessible and usable for researchers, scholars, and students in the future.

Submission Turnaround Time